Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise in halting lung cancer progression after standard treatment

NCT ID NCT03706690

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 10, 2025 · Last updated May 16, 2026 · Updated 21 times

Summary

This study tested whether the drug durvalumab can help people with stage III lung cancer that cannot be surgically removed. After completing chemotherapy and radiation, 407 participants received either durvalumab or a placebo every few weeks. The goal was to see if durvalumab could delay cancer growth or improve survival. Results showed that durvalumab significantly extended the time before the cancer worsened compared to placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Beijing, 100021, China

  • Research Site

    Beijing, 100142, China

  • Research Site

    Beijing, 100730, China

  • Research Site

    Beijing, 100853, China

  • Research Site

    Bengbu, 233004, China

  • Research Site

    Changchun, 130000, China

  • Research Site

    Changchun, 510000, China

  • Research Site

    Changsha, 410013, China

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Chengdu, 610042, China

  • Research Site

    Chengdu, 610072, China

  • Research Site

    Chongqing, 400037, China

  • Research Site

    Fuzhou, 350011, China

  • Research Site

    Guangzhou, 510280, China

  • Research Site

    Hangzhou, 310003, China

  • Research Site

    Hangzhou, 310006, China

  • Research Site

    Hangzhou, 310022, China

  • Research Site

    Harbin, 150081, China

  • Research Site

    Linhai, 317000, China

  • Research Site

    Nanjing, 210009, China

  • Research Site

    Nanning, 530021, China

  • Research Site

    Ningbo, 315010, China

  • Research Site

    Qingdao, 266042, China

  • Research Site

    Shanghai, 200030, China

  • Research Site

    Shanghai, 200032, China

  • Research Site

    Shanghai, 200433, China

  • Research Site

    Shenyang, 110042, China

  • Research Site

    Ürümqi, 830000, China

  • Research Site

    Wenzhou, 325000, China

  • Research Site

    Wuhan, 430030, China

  • Research Site

    Yangzhou, 225001, China

  • Research Site

    Zhengzhou, 450000, China

  • Research Site

    Zhengzhou, 450008, China

  • Research Site

    Hong Kong, 00000, Hong Kong

  • Research Site

    Bangalore, 560068, India

  • Research Site

    Bengaluru, 560076, India

  • Research Site

    Karamsad, 388325, India

  • Research Site

    Kolkata, 700160, India

  • Research Site

    Nashik, 422005, India

  • Research Site

    Vadodara, 390007, India

  • Research Site

    Culiacán, 80230, Mexico

  • Research Site

    Mexico City, 0 3100, Mexico

  • Research Site

    Mexico City, 11810, Mexico

  • Research Site

    México, 1400, Mexico

  • Research Site

    Monterrey, 64000, Mexico

  • Research Site

    San Luis Potosí City, 78250, Mexico

  • Research Site

    Bacolod, 6100, Philippines

  • Research Site

    Baguio City, 2600, Philippines

  • Research Site

    Cagayan de Oro, 9000, Philippines

  • Research Site

    Cebu, 6000, Philippines

  • Research Site

    Davao City, 8000, Philippines

  • Research Site

    Quezon City, 1100, Philippines

  • Research Site

    Quezon City, 1104, Philippines

  • Research Site

    San Juan City, 1502, Philippines

  • Research Site

    Bialystok, 15-540, Poland

  • Research Site

    Gdansk, 80-952, Poland

  • Research Site

    Poznan, 60-569, Poland

  • Research Site

    Tomaszów Mazowiecki, 97-200, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Kazan, Tatarstan, 420029, Russia

  • Research Site

    Kirov, 610021, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Moscow, 121467, Russia

  • Research Site

    Murmansk, 183047, Russia

  • Research Site

    Novosibirsk, 630055, Russia

  • Research Site

    Novosibirsk, 630099, Russia

  • Research Site

    Obninsk, 249036, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Samara, 443031, Russia

  • Research Site

    Saransk, 430005, Russia

  • Research Site

    Volgograd, 400138, Russia

  • Research Site

    Daegu, 41944, South Korea

  • Research Site

    Gwangju, 61469, South Korea

  • Research Site

    Seoul, 08308, South Korea

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Tainan, 70403, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Taipei, 11217, Taiwan

  • Research Site

    Taipei, 114, Taiwan

  • Research Site

    Taipei, 235, Taiwan

  • Research Site

    Taoyuan, 333, Taiwan

  • Research Site

    Adana, 01060, Turkey (Türkiye)

  • Research Site

    Ankara, 06340, Turkey (Türkiye)

  • Research Site

    Edirne, 22030, Turkey (Türkiye)

  • Research Site

    Istanbul, 34030, Turkey (Türkiye)

  • Research Site

    Konya, 42080, Turkey (Türkiye)

  • Research Site

    Malatya, 44100, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG